Saudi Fund for Development CEO Receives Sierra Leone's Foreign Minister    Public Investment Fund Launches "Savvy Gaming Group"    Diriyah E-Prix 2-Time Champion Sam Bird Sets His Sight on More Triumph in 2022 Diriyah E-Prix    Minister of Islamic Affairs: Kingdom seeks to serve Islam and Muslims around world    Ministry of Health Reports 4,526 New COVID-19 Cases, 5,772 Recoveries in Saudi Arabia    Asian Shares Mixed    [email protected]: Set to become world's technological and economic powerhouse    Royal Commission in Yanbu Achieves Arab Award for Operation and Maintenance    IPA organizes 'Innovation and the Future of Government Work' conference on February 9    NDMC clears 43% of debts due for payment in 2022    Flying car cleared for takeoff, but you'll need a pilot's license    Crown Prince, Chan-o-cha reaffirm need to open a new chapter in Saudi-Thai relations    Dozens feared lost as 'smuggling' boat capsizes off Florida    Netherlands to ease Covid restrictions despite rising case numbers    What the grand Republic Day parade means to India    Unvaccinated man denied heart transplant by Boston hospital    Deputy Ruler of Sharjah witnesses premiere of 'Narratives of the Place'    Sir Elton John postpones US shows after positive Covid-19 test    Bollywood's Shilpa Shetty cleared of obscenity over Richard Gere kiss    Egypt Records 1809 New Cases of COVID-19    Weather Forecast for Wednesday    Commerce Minister: Prime Minister of Thailand visit comes within Saudi Arabia's keenness to strengthen relations with countries of world    Minister of Justice Meets with His British Counterpart    Non-oil exports in Saudi Arabia increase by 26.1%    At least six killed in Cameroon stadium stampede    Al Hilal pays tribute to departing star striker Bafetimbi Gomis    Mauritania Condemns Houthi Terrorist Attacks on Saudi Arabia and UAE    Saudi Stock Exchange Main Index Ends Trading Higher at 12,108 Points    General Court of Audit President Inaugurates 8th Conference for Internal Audit with Int'l Participation    UN chief calls for Olympic Truce to build 'culture of peace' through power of sport    Taylor Swift slams Damon Albarn over songwriting comments    Australian Open: Peng Shuai T-shirt ban reversed after outcry    Cirque du Soleil to establish an academy and regional office in Saudi Arabia    Omani National Football Team Arrives in Jeddah to Meet Saudi National Team    'Bab Al Hara' Director Bassam AlMulla passes away at 65    Saudi Handball Team Loses to Qatar in Main Round of 2022 Asian Men's Handball Championship    Eighth Season of ABB FIA Formula E World Championship to kick off in Diriyah    Riyadh's Qualitative Events Enrich its Winter, Attract World Attention    SFDA: Fat is a Source of Energy and Its Abundance is Linked to Chronic Diseases    Reflections on celebration of Christmas    Royal Commission for AlUla to Hold Custodian of the Two Holy Mosques Endurance Cup 2022, Richard Mille AlUla Desert Polo    Saudi Arabia's Pavilion at Expo 2020 Dubai Organizes a Dance Theatrical Show for Children    Saudi Arabia rebuffs UN resolution on 'sexual orientation'    Kabir Khan eyes on joint Indian – Saudi film projects    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Pfizer says coronavirus vaccine is 100% effective in kids ages 12 to 15
Published in The Saudi Gazette on 31 - 03 - 2021

Clinical trial results of Pfizer/BioNTech's COVID-19 vaccine showed its efficacy is 100 percent and it is well tolerated in youths ages 12 to 15, the manufacturer said on Wednesday.
Pfizer/BioNTech plans to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine.
In a Phase 3 trial of 2,260 participants ages 12 to 15 in the US, the vaccine elicited strong antibody responses one month after the second dose — exceeding those demonstrated in people ages 16 to 25 in previous trials, Pfizer reported. The vaccine is currently authorized in the US for emergency use in people 16 and older.
Researchers observed 18 COVID-19 cases among the 1,129 participants who were given a placebo, and none among the 1,131 volunteers who got the vaccine. The data has yet to be peer reviewed.
Pfizer/BioNTech added that the side effects seen in the young teens were similar to those seen among 16 to 25-year-olds. Common side effects include pain at the injection site, fatigue and fever. The participants will be monitored for protection and safety for two years after their second dose.
Those comparisons to the older population are important because researchers are building off of the knowledge they gained in the adult trials.
Researchers can define a number of antibodies that are a correlate of the protection seen in adults, and then look for that level of antibodies in pediatric participants to know that the vaccine is providing protection. That's why the COVID-19 vaccine trials in children and adolescents have generally required fewer volunteers than the adult trials.
"We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15," said Pfizer CEO Albert Bourla.
"We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year."
Dr. William Gruber, Pfizer's senior vice president of vaccine clinical research and development also noted last week that the vaccine could be ready for this age group by the upcoming school year.
A return to the classroom isn't the only factor at play. Health experts have emphasized the importance of protecting as many people as possible through vaccination, as more infectious COVID-19 variants continue to spread throughout the nation.
"We all long for a normal life. This is especially true for our children," said BioNTech CEO Ugur Sahin. "The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant."
Pfizer recently told CNN that the safety demonstrated in this adolescent trial helped the company make the decision to begin testing its vaccine in younger children.
A separate Phase 1/2/3 study of the Pfizer/BioNTech vaccine in children ages 6 months to 11 years launched last week, when the first children ages 5 to 11 received a shot. Pfizer/BioNTech plans to begin dosing 2 to 5-year-olds next week and work its way down to participants ages 6 months to 2 years. The company aims to enroll 4,644 children in the trial and expects results by the end of 2021.
Moderna is also testing its vaccine in adolescents and children, in two clinical trials of children ages 12 to 17 and those ages 6 months to 11 years.
Experts anticipate Covid-19 vaccines won't be available for children 11 and younger in time for the upcoming school year. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said those younger children may have to wait until the first quarter of 2022.
Dr. Buddy Creech, director of Vanderbilt University's Vaccine Research Program and an investigator in Moderna's pediatric trials, estimates a COVID-19 vaccine could be available for high-risk kids 12 and older by July or August, but likely won't be available for children 11 and younger until November or December, at the earliest. — Courtesy CNN


Clic here to read the story from its source.